Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 1, 1999 - Issue 1
Submit an article Journal homepage
153
Views
17
CrossRef citations to date
0
Altmetric
Miscellaneous

Sildenafil

Jon Cartledge Pyrah Department of Urology, St James University Hospital, Beckett Street, Leeds, LS9 7TF, UK. [email protected]
&
Ian Eardley Pyrah Department of Urology, St James University Hospital, Beckett Street, Leeds, LS9 7TF, UK. [email protected]
Pages 137-147 | Published online: 24 Feb 2005

Bibliography

  • KRANE RJ, GOLDSTEIN I, SAENZ DE TEJADA I: Impotence. New Eng]. J. Med. (1989) 321 (24) :1648–1659.
  • ••A description of the haemodynamics of erection.
  • FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and physiological correlates: results of the Massachu- setts male ageing study. J. Ural. (1994) 151:54–56.
  • •A large epidemiological study of the incidence of ED.
  • WITHERINGTON R: Vacuum constriction device formanagement of erectile impotence. J. Urol. (1989) 141:320–322.
  • LINET 01, OGRINC FG: Efficacy and safety of intracaver-nosal alprostadil in men with erectile dysfunction. New Engl. J. Med. (1996) 334:873–877.
  • PADMA-NATHAN H, HELLSTROM W, KAISER FE et al:Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl. J. Med. (1997) 336:1–7.
  • VARDI Y, SIROKY MB: Hemodynamics of pelvic nerveinduced erection in a canine model. I. Pressure and flow. J. Urol. (1990) 144:794–797.
  • BLANCO R, SAENZ DE TEJADA I, GOLDSTEIN I, KRANE RJ,WOTIZ HH, COHEN RA: Cholinergic neurotransmis-sion in human corpus cavernosum. II. Acetylcholine synthesis. Am. J. Physic)]. (1988) 254(3):H468–H472.
  • BANYA Y, USHIKI T, TAKAGANE H, AOKI H, KUBO T,OHHORI T, IDE C: Two circulatory routes within the human corpus cavernosum penis: a scanning electron microscopic study of corrosion casts. J. Urol. (1989) 142:879–883
  • ANDERSSON K-E, STEIF CG: Neurotransmission and thecontraction and relaxation of penile erectile tissues. World J. Urol. (1997) 15:14–20.
  • KIM N, AZADZOI KM, GOLDSTEIN I, SAENZ DE TEJADA I: A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Invest. (1991) 88:112–118.
  • •The first report on the role of NO in penile erection.
  • RAJFER J, ARONSON WJ, BUSH PA, DOREY FJ, IGNARRO LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. New Engl. J. Med. (1992) 326:90–94.
  • BURNETT AL, LOWENSTEIN CJ, BREDT DS, CHANG TSK,SNYDER SH: Nitric oxide: a physiological mediator of penile erection. Science (1992) 257:401–403.
  • PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from t-arginine. Nature (1988) 333:664–666.
  • STIEF CG, NOACK T, ANDERSSON K-E: Signal transduc- tion in cavernous smooth muscle. World J. Urol. (1997) 15:27–31.
  • •A summary of intracellular events in the control of penile smooth muscle.
  • TAHER A, MEYER M, STIEF CG, JONAS U, FORSSMANN WG: Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. WorldJ. Urol. (1997) 15:32–35.
  • BOOLELL M, ALLEN MJ, BALLARD SA et al: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodies-terase inhibitor for the treatment of penile erectile dysfunction. Int. J. Imp. Res. (1996) 8:47–52.
  • BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75(4):725–748.
  • ••A comprehensive review of PDE biology.
  • BEAVO JA, CONTI M, HEASLIP RJ: Multiple cyclic-nucleotide phosphodiesterases. Mol. Pharmacol (1994) 46:399–405.
  • SAMLASKA CP, WINFIELD EA: Pentoxifylline. J. Am.Acad. Dermatol. (1994) 30:603–621.
  • KUKOVETZ WR, POCH G: Inhibition of cyclic-3',5'-nucleotide phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs. Naunyn-Schmied. Arch. PharmacoL (1970) 267:189–194.
  • BRADING AF, BURDYGA TV, SCRIPNYUK ZD: The effects of papaverine on the electrical and mechanical activity of the guinea pig ureter. J. Physiol. (1983) 334:79.
  • BALLARD SA, TURNER LA, NAYLOR AM: Sildenafil, a potent selective inhibitor of type-5 phosphodiesterase enhances nitric oxide dependent relaxation of rabbit corpus cavernosum. Br. J. Pharmacol. (1996) 118:153P.
  • JEREMY JY, BALLARD SA, NAYLOR AM, MILLER MAW, ANGELLINI GD: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. (1997) 79:958–963.
  • MORELAND RB, GOLDSTEIN I, TRAISH A: Sildenafil, a novel inhibitor of phosphodiesterase Type 5 in human corpus cavernosum smooth muscle cells. Life Sci. (1998) 62 (20):PL309–318.
  • CARTER AJ, BALLARD SA, NAYLOR AM: The effect of sildenafil (Viagra') on erectile function in the anaesthetised dog. J. Urol. (1997) 157 (Suppl.):A1398
  • Viagra (sildenafil citrate) data sheet. (Nov 1998). Pfizer, Inc., NY, USA.
  • ITO M, NISHIKAWA M, FUJOKI M, MIYAHARA M, ISAKA N, SHIKU H, NAKANO T: Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell. Signal. (1996) 8(8):575–581.
  • EARDLEY I, BROOK J, YATES PK, WULFF MB, BOOLELL M: Sildenafil (Viagra"), a novel oral treatment with rapid onset of action for penile erectile dysfunction. Br. J. Urol. (1997) 79 (Suppl. 4):66.
  • MAYTOM MC, DERRY FA, DINSMORE WW et al. A Two-part pilot study of sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord (1999) 37(2) 110–116
  • JACKSON G, BENJAMIN N, JACKSON N, ALLEN MJ: Effectsof sildenafil citrate on human hemodynamics. Am. J. Cardiol. (1999) 83 (5A):13C–20C.
  • WEBB DJ, FREESTONE S, ALLEN MJ, MUIRHEAD GJ: Sildenafil citrate and blood-pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol. (1999) 83 (5A):21C–28C.
  • VOBIG MA, KLOTZ T, STAAK et al.: Retinal side effects of sildenafil [letter]. Lancet (1999) 353:375.
  • ZRENNER E: No cause for alarm over retinal side effects of sildenafil. Lancet (1999) 353:340–341.
  • VEMULAPALLI S, WATKINS RW, CHINTALA M et al.: Antiplatelet and antiproliferative effects of SCH 51866, a novel Type 1 and Type 5 phosphodiesterase inhibitor. J. Cardiovasc. Pharmacol (1996) 28(6)862–829.
  • BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: anorally active Type 5 cyclic GMP-specific phosphodies-terase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8(2):47–52.
  • WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissuedistribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83 (5A) :3C–12C.
  • MUIRHEAD GJ, ALLEN MJ, JAMES GC et al. Pharmacoki- netics of sildenafil (Viagra) a selective cGMP PDE 5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br. J. Pharmacol 42(2) 268P
  • ZUSMAN RM, MORALES A, GLASSER DB, OSTERLOH IH:Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol (1999) 83:35C–44C.
  • BOOLELL M, GEPI-ATTEE S, GINGELL JC, ALLEN MJ:Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br. J. Urol. (1996) 78(2):257–261.
  • •Early data on the use of sildenafil in men with ED.
  • GINGELL JC, JARDIN A, OLSSON AM et al.: UK-92,480, anew oral treatment for erectile dysfunction: a double-blind placebo-controlled, once daily dose response study. J. Oro]. (1996) 155 (Suppl.):495A.
  • EARDLEY I, MORGAN RJ, DINSMORE WW et al.: UK-92,480, a new oral treatment for erectile dysfunc-tion: a double-blind placebo-controlled trial with treatment taken as required. J. Urol. (1996) 155 (Suppl.):495A.
  • VIRAG R, HODGES M, HOLLINGSHEAD M, KIRKPATRICKJ, OSTERLOH IH: Sildenafil (Viagra) a new oral treatment for erectile dysfunction: an 8 week double blind, placebo controlled parallel group study. Int. J. Impot. Res. (1997) 8:A70. Exp. Opin. Pharmacother. (1999) 1(1)
  • GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction. New Engl. J. Med. (1998) 338:1397–1404.
  • ••Large, multicentre trial.
  • ROSEN RC, RILEY A, WAGNER G, OSTERLOH IH, KIRKPATRICK J, MISHRA A: The International Index for Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology (1997) 49:822–829.
  • MARKS LS, DUDA C, DOREY FJ, MACAIRAN ML, SANTOS PB. Treatment of erectile dysfunction with sildenafil. Urology (1999) 53:19–24
  • PRICE DE, GINGELL JC, GEPI-ATTEE S, WAREHAM K, YATES P, BOOLELL M: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet. Med. (1998) 15(10):821–825.
  • RENDELL MS, RAJFER J, WICKER PA, SMITH MD, SILDENAFIL DIABETES STUDY GROUP: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA (1999) 281 (5):421–426.
  • DERRY FA, DINSMORE WW, FRASER M, GARDNER BP, GLASS CA, MAYTOM MC, SMITH MD: Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunc-tion caused by spinal cord injury. Neurology (1998) 51 (6) :1629–1633.
  • HOLMGREEN E, GIULIANO F, HULTING C etal: Sildenafil (Viagra) in the treatment of erectile dysfunction (ED) caused by spinal cord injury (SCI): a double-blind, placebo controlled, flexible dose, two way crossover study. Neurology (1998) 50(Suppl.):A127.
  • ZIPPE CD, KEDIA AW, KEDIA K, NELSON DR, AGARWAL A: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology (1998) 52:963–966.
  • OSTERLOH IH: Sildenafil (Viagra); overall safety profile in 18 double-blind, placebo controlled clinical trials of erectile dysfunction. Int. J. Impot. Res. (1998) 10(3):S31.
  • MORALES A, GINGELL C, COLLINS M, WICKER PA, OSTERLOH IH: Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int. J. Impot. Res. (1998) 10(2):69–73.
  • MORALES A, HEATHCOTE P: Oral sildenafil (Viagra) in the treatment of erectile dysfunction: efficacy of 50 mg, 100 mg and 200 mg doses. Int. J. Impot. Res. (1998) 10(3):S40.
  • CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol (1999) 83 (5A):29C–34C.
  • CHEITLIN MD, HUTTER AM JR., BRINDIS RG, GANZ P, RUSSELL RO JR, ZUSMAN RM. ACC/AHA expert consensus document. Use of sildenafil (Viagra') in patients with cardiovascular disease. J. Am. Coll. Cardiol. (1999) 33:273–282.
  • MULLER JE, MITTLEMAN A, MACLURE M, SHERWOOD JB, TOFLER GH: Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. JAMA (1996) 275:1405–1409.
  • GINGELL C, WRIGHT P, BARNES T et al.: Guidance on the management of erectile dysfunction in primary care. Prescriber (1999) (Suppl. 5 June):1–16.
  • EARDLEY I: New oral therapies for erectile dysfunc-tion. Br. J. Urol. (1998) 81:122–127.

Websites

  • http://www.fda.gov/cder/consumerinfo/viagra/ safety3.htm Summary of reports of death in Viagra users received from marketing (late March) through mid-November 1998. (October 1999).
  • •Up-to-date information on the safety of sildenafil from reports to the FDA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.